Brought to you by 
Merck pays $230mm up front for rights to four of Vertex's oncology programs; Vertex gets back some rights
29 Oct 2021
Executive Summary
Merck KGAA licensed global rights to four of Vertex Pharmaceuticals Inc.’s oncology programs, expanding Merck’s cancer pipeline to include new DNA damage and repair candidates, as well as an immuno-oncology compound.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck pays $230mm up front for rights to four of Vertex's oncology programs; Vertex gets back some rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice